Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.
about
Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adultsClinical trial design and selected drug safety issues for antibiotics used to treat community-acquired pneumoniaAntibiotic Prescriptions and Prophylaxis in Italian Children. Is It Time to Change? Data from the ARPEC Project.Atypical aetiology in patients hospitalised with community-acquired pneumonia is associated with age, gender and season; a data-analysis on four Dutch cohortsCausative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban populationMycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ).Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia."Ten Commandments" for the Appropriate use of Antibiotics by the Practicing Physician in an Outpatient SettingRapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection.Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.High-Throughput Intracellular Antimicrobial Susceptibility Testing of Legionella pneumophila.Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomesSwedish guidelines for the management of community-acquired pneumonia in immunocompetent adults.Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.Recent changes in the management of community acquired pneumonia in adultsControversies in the treatment of pneumococcal community-acquired pneumonia.Issues in noninferiority trials: the evidence in community-acquired pneumonia.Evolution of acute infection with atypical bacteria in a prospective cohort of children with community-acquired pneumonia receiving amoxicillin.Treatment of chlamydial infections.Elderly patients with community-acquired pneumonia: optimal treatment strategies.Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection.Current treatment of community-acquired pneumonia.The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia.A step forward in the everyday management of adults with community acquired pneumonia.Additional corticosteroids or alternative antibiotics for the treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia.Community acquired pneumonia: Antibiotic coverage is atypical: evidence from randomised trialsEuropean Surveillance of Antimicrobial Consumption (ESAC): outpatient use of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in Europe (1997-2009).Treatment of acute cough/lower respiratory tract infection by antibiotic class and associated outcomes: a 13 European country observational study in primary care.Definite, probable, and possible bacterial aetiologies of community-acquired pneumonia at different CRB-65 scores.Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.A worldwide perspective of atypical pathogens in community-acquired pneumonia.Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia.The dilemma of monotherapy or combination therapy in community-acquired pneumonia.The efficacy of high-dose penicillin G for pneumococcal pneumonia diagnosed based on initial comprehensive assessment at admission: an observational study.Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia.
P2860
Q24200609-1B486E9F-0FD2-4F40-86A7-0E1CDCDA8A63Q24654370-7BC07D78-CC0E-4490-94CA-F1DBB8117FFFQ31096335-63B032A2-BC12-47CF-8E6D-6E12944253EBQ31108856-92C42B94-04F0-4DEF-8556-BF5936E6C91DQ33418963-AC8F5735-4B36-4482-BE4F-C946B3F6A1C3Q33445332-36B82111-5DB6-46F9-A069-C277EC61B57BQ33684318-A6B566D5-7A30-4B9F-B0DF-D43A696FC11CQ35575828-F8440182-B9E7-4A6D-9A4A-6DC7D24BD75DQ36087389-F1BCE2A7-56B3-441B-86D6-F1251E3D7255Q36281234-1FF93CCF-B8A1-4EAE-B2A8-9546E8FAF000Q36290493-506BDCEE-7B9C-4DFB-BA0A-81B547E9799CQ36291044-0421F6F3-F28A-497B-ACA7-D88731C597C6Q36343776-06F9F173-D41D-4F57-9956-10DBD17C71E8Q36391382-2F1D5AEA-46AA-48B8-8090-2E37A37605F6Q36728885-33761A21-6727-4C56-AB0C-0364403A7538Q36895630-7420E716-C4C3-4135-9862-0B0F8B382F67Q37170063-2A3F7DAB-944D-44D5-AADC-63ED730D2402Q37834287-0CCEC463-A8E9-48E7-853A-0D06960020E1Q37849351-0D3D9850-D584-4F4F-8084-072929F0FF1BQ37896600-6281FB82-1B1D-4798-B78B-020B3B264C48Q38061407-54BD4F94-9A54-496E-A21A-0D80EC7394D6Q38105639-9962CE4F-9740-4B96-A0FD-4278697C9845Q38601840-2F80F00D-4A00-4A64-A5CA-8EC7E9C88F8FQ41108630-5EFE0D47-4A7F-418C-877C-9B1CFCB9D725Q42375907-185FC467-81CC-40AD-864F-2E3CAFA96FEDQ42738561-AB46BFE3-8611-4792-9E53-8F74621CA892Q43593444-1AE40CAA-1D46-470F-BB77-B50DC508C673Q45573970-83DF84D3-A1FF-4E22-9216-9616CF395F49Q45975061-26C456E3-C62B-43A7-A0D3-A000EB94BEA9Q46263023-0189326F-539E-4855-B3DF-28222C469184Q46353484-2AA26ADC-D259-41D4-870C-88AEF3A7B40CQ46887329-743082C0-B91A-412A-A642-E3DB7E05933EQ47291065-9F1988B2-7E05-481C-BF73-D77D2087A9B4Q55442896-E1E92E53-8838-40A8-915E-E03CC12A79BBQ55519153-27758879-C25A-44A0-8443-76EF7BFFB471
P2860
Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Effectiveness of beta lactam a ...... ired pneumonia: meta-analysis.
@ast
Effectiveness of beta lactam a ...... ired pneumonia: meta-analysis.
@en
type
label
Effectiveness of beta lactam a ...... ired pneumonia: meta-analysis.
@ast
Effectiveness of beta lactam a ...... ired pneumonia: meta-analysis.
@en
prefLabel
Effectiveness of beta lactam a ...... ired pneumonia: meta-analysis.
@ast
Effectiveness of beta lactam a ...... ired pneumonia: meta-analysis.
@en
P2093
P2860
P1433
P1476
Effectiveness of beta lactam a ...... ired pneumonia: meta-analysis.
@en
P2093
Bruce Arrol
Graham D Mills
Michael R Oehley
P2860
P356
10.1136/BMJ.38334.591586.82
P407
P577
2005-01-31T00:00:00Z